Elicio Therapeutics (ELTX) Fundamental Analysis: Revenue, Earnings & Valuation

3.71 / 10

Netural

Fundamental metrics indicate poor status (3.7/10). Bullish considerations: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, though challenges appear in Asset-MV and Fixed assets turnover ratio. Final rating: guarded.

Analysis Checks(7/10)

Revenue-MV

Value-0.18

Score3/3

Weight60.66%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value142.08

Score2/3

Weight2.44%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-6.36%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight26.47%

1M Return4.10%

PB-ROE

Value3.85

Score0/3

Weight9.57%

1M Return1.47%

Fixed assets turnover ratio

Value8528.00

Score1/3

Weight-9.20%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-5.90%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value185.72

Score2/3

Weight4.07%

1M Return0.68%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-7.40%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight25.65%

1M Return3.90%

Is ELTX fundamentally strong?

ELTX scores 3.71/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -4.95 P/E ratio, 119.75 P/B ratio, and 39.29% earnings growth, these metrics solidify its Netural investment rating.